Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Junctional Adhesion Molecule-A/F11 Receptor (JAM-A/F11R) Is a Novel Biomarker and a Potential Treatment Target In Multiple Myeloma Tumor and Its Microvascular Milieu

Bani M Azari, MD/PhD, Danielle F Joseph, PhD, Marc J Braunstein, MD/PhD, H. Uwe Klueppelberg, MD, Eric LP Smith, PhD, Sadeaqua Scott, PhD, Jonathan D Marmur, MD, Anna Babinska, PhD, Olcay Batuman, MD

Blood (2010) 116 (21): 450.

https://doi.org/10.1182/blood.V116.21.450.450

Published: 2010

Journal Articles

Endothelial Progenitor Cells within the Bone Marrow Microenvironment of Multiple Myeloma Patients Display Stem Cell Traits.

Sadeaqua S. Scott, BS, Marc J. Braunstein, BS, Christopher Lange, PhD, Christopher Roman, PhD, Uwe Klueppelberg, MD, Olcay Batuman, MD

Blood (2009) 114 (22): 2816.

https://doi.org/10.1182/blood.V114.22.2816.2816

Published: 2009

Journal Articles

Targeting Hsp70 in Multiple Myeloma Induces Synergistic Cytotoxicity with Inhibitors of the Proteasome and of Hsp90

Marc J Braunstein, Craig M Scott, Shannon Behrman, Peter Walter, PhD, Peter Wipf, PhD, Eric LP Smith, PhD, Sadeaqua S Scott, BA, H. Uwe Klueppelberg, MD, Jeffrey L Brodsky, PhD, Olcay Batuman, MD

Blood (2008) 112 (11): 5160.

https://doi.org/10.1182/blood.V112.11.5160.5160

Published: 2008

Journal Articles

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Zoledronate, Dexamethasone, and Low-Dose Thalidomide: A Phase II Trial.

Uwe Klueppelberg, MD, PhD, Eric L.P. Smith, PhD, Marc J. Braunstein, MD, PhD candidate, David Kahn, MD, Olcay A. Batuman, MD

Blood (2006) 108 (11): 5124.

https://doi.org/10.1182/blood.V108.11.5124.5124

Published: 2006

Journal Articles

Differential Effects of Hsp70 Inhibition within the Tumor and Microenvironment in Multiple Myeloma.

Marc J. Braunstein, MD, PhD, Na Liu, MD, Uwe Klueppelberg, MD,PhD, Craig Scott, Shannon Behrman, Can Tamucin, Peter Walter, PhD, Peter Wipf, PhD, Jeffrey Brodsky, PhD, Olcay Batuman, MD

Blood (2006) 108 (11): 5070.

https://doi.org/10.1182/blood.V108.11.5070.5070

Published: 2006

Journal Articles

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.

Uwe Klueppelberg, MD, PhD, Iuliana Shapira, MD, Eric Smith, PhD, Marc Braunstein, BS, David Kahn, MD, Yury Pertsovsky, Olcay Batuman, MD

Blood (2005) 106 (11): 5180.

https://doi.org/10.1182/blood.V106.11.5180.5180

Published: 2005

Journal Articles

Evidence for Clonality in Circulating Endothelial Progenitor Cells in Multiple Myeloma.

Tayfun Ozcelik, MD, Varsha Vakil, Eric Smith, PhD, Marc Braunstein, Justin Maroney, Uwe Klueppelberg, MD PhD, Sevgi Bagislar, Cemaliye Akyerli, Olcay Batuman, MD

Blood (2004) 104 (11): 2357.

https://doi.org/10.1182/blood.V104.11.2357.2357

Published: 2004

Journal Articles

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Uwe Klueppelberg, MD PhD, Eric Smith, PhD, Laurie Chen, MD, Chona M. Aloba, MD, Iuliana Shapira, MD, Mehdi M. Moezi, MD, Olcay Batuman, MD

Blood (2004) 104 (11): 4932.

https://doi.org/10.1182/blood.V104.11.4932.4932

Published: 2004

NARROW

Junctional Adhesion Molecule-A/F11 Receptor (JAM-A/F11R) Is a Novel Biomarker and a Potential Treatment Target In Multiple Myeloma Tumor and Its Microvascular Milieu

Endothelial Progenitor Cells within the Bone Marrow Microenvironment of Multiple Myeloma Patients Display Stem Cell Traits.

Targeting Hsp70 in Multiple Myeloma Induces Synergistic Cytotoxicity with Inhibitors of the Proteasome and of Hsp90

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Zoledronate, Dexamethasone, and Low-Dose Thalidomide: A Phase II Trial.

Differential Effects of Hsp70 Inhibition within the Tumor and Microenvironment in Multiple Myeloma.

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.

Evidence for Clonality in Circulating Endothelial Progenitor Cells in Multiple Myeloma.

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only